Ageas/ NV (CHIX:AGSB) Research & Development: €0 Mil (TTM As of Dec. 2025)


CHIX:AGSB Ageas SA/ NV CHIX:AGSB
69 GF Score
Price €68.18
GF Value €55.63
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ageas/ NV Research & Development?

Ageas/ NV CHIX:AGSB 69 Research & Development is €0 Mil as of Dec. 2025. GuruFocus rates CHIX:AGSB with a GF Score™ of 69/100 and a GF Value™ of €55.63 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ageas/ NV's Research & Development for the six months ended in Dec. 2025 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Ageas/ NV  (CHIX:AGSb) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ageas/ NV Research & Development Related Terms

Ageas/ NV Research & Development Historical Data

* Premium members only.

The historical data trend for Ageas/ NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ageas/ NV Research & Development Chart

Ageas/ NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ageas/ NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:AGSB
69GF Score
Ageas SA/ NV CHIX:AGSB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ageas/ NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Ageas/ NV (CHIX:AGSB) has a Research & Development of €0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Ageas/ NV and its competitors.
Is Ageas/ NV's Research & Development too high?
Ageas/ NV's current Research & Development is €0 Mil. Overall, Ageas/ NV has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ageas/ NV's Research & Development compare to BRK.A and AIG?
Ageas/ NV's Research & Development of €0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ageas/ NV and its competitors. Ageas/ NV's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ageas/ NV stock overvalued right now?
Based on GuruFocus' analysis, Ageas/ NV (CHIX:AGSB) is currently considered Modestly Overvalued. The stock's GF Value™ is €55.63, compared to a current price of €68.18 — trading 22.6% above its estimated fair value. The current Research & Development is €0 Mil. Ageas/ NV's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ageas/ NV (CHIX:AGSB), the current Research & Development is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ageas/ NV (CHIX:AGSB) Overvalued in 2026?

Based on GuruFocus' analysis, Ageas/ NV stock appears to be overvalued. The current stock price of €68.18 is trading 22.6% above its estimated GF Value™ of €55.63. GuruFocus considers Ageas/ NV to be Modestly Overvalued.

Key valuation signals for CHIX:AGSB:

  • Research & Development: €0 Mil
  • GF Value™: €55.63 vs. price of €68.18 (22.6% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AGSB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ageas/ NV Business Description

Address Avenue Du Boulevard 21, Manhattan Center, Saint-Josse-ten-Noode, Brussels, BEL, 1210
Ageas was spun out of Fortis during the financial crisis after a consortium including Banco Santander and Royal Bank of Scotland launched a failed bid for ABN Amro. The takeover was badly timed and overly ambitious, and to fund it Fortis started selling noncore divisions while writing down collateralized debt. As Fortis' capital began to decline, the company initiated a rights issue, and suspended the dividend. As Fortis' share price began to decline and financial market conditions continued to deteriorate, with a series of leadership changes, customers began to withdraw deposits. Fortis was approached by the government and sold its domestic banking operations to the Belgian government. It also spun off its asset management and insurance units which later became Ageas.
69GF Score

Get the complete analysis for CHIX:AGSB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.18
Price
€55.63
GF Value